Salivary eicosanoid concentration in patients with Sjogren's syndrome

Article Abstract:

Screening tests for thromboxane B2 (TxB2) and prostaglandin E2 (PGE2) levels in saliva may be useful in identifying patients with primary Sjogren's syndrome (SS). TxB2 and PGE2 are hormone-like chemical compounds that stimulate cell activity and may play a role in the inflammation process. Researchers measured the TxB2 levels in the saliva of 18 patients with documented primary SS, 10 patients with dry mouth and 18 healthy volunteers (controls). They measured PGE2 levels in 11 of the patients with primary SS, 5 patients with dry mouth, and 8 controls. TxB2 levels were significantly higher in the patients with primary SS (1.95 nanograms per milliliter (ng/ml)) as compared to the patients with dry mouth (0.52 ng/ml) or the controls (0.3 ng/ml). Patients with primary SS also had higher levels of PGE2 (3.75 ng/ml) than the patients with dry mouth (0.32 ng/ml) or the controls (0.41 ng/ml).

Analysis, Diagnosis, Measurement, Prostaglandins, Eicosanoic acid

---

Salivary and serum hyaluronic acid concentrations in patients with Sjogren's syndrome

Article Abstract:

Increased salivary hyaluronic acid (HA) levels may indicate inflammation in the mouth associated with Sjogren's syndrome. Sjogren's syndrome is an autoimmune disease which causes dry-mouth and dry eyes from diminished tear and saliva flow. Researchers compared 39 Sjogren's syndrome patients with 19 dry-mouth patients and 10 healthy volunteers. Salivary HA levels were lowest in healthy volunteers, higher in patients with dry-mouth, and substantially higher in those with Sjogren's syndrome. Measurement of salivary HA may be useful in the diagnosis of the condition.

Physiological aspects, Hyaluronic acid, Xerostomia

---

Hydroxychloroquine treatment for primary Sjogren's syndrome: its effect on salivary and serum inflammatory markers

Article Abstract:

Hydroxychloroquine may provide an effective treatment for Sjogren's syndrome, and it is to be hoped that a full scale double blind controlled study be undertaken to discover the therapeutic extent. In an open prospective study, 14 patients with Sjogren's syndrome were given 200 mg./day for 12 months. There was enough amelioration of salivary dryness and swelling to warrant further investigation, although imporvement in the markers was only seen at the end, after 12 months.

Research, Evaluation, Hydroxychloroquine

Similar abstracts:

• Abstracts: Mortality among children with Kawasaki disease in Japan. Serum concentrations of total bile acids in patients with acute Kawasaki syndrome
• Abstracts: Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. New therapies for cytomegalovirus retinitis
• Abstracts: Survival effects of ZDV, ddI, and ddC on patients with CD4 <= 50 cells/mm3. Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression
• Abstracts: Comparison of intrauterine hematologic and biochemical values between twin pairs with and without stuck twin syndrome
• Abstracts: Preterm delivery from 34 to 37 weeks of gestation: is respiratory distress syndrome a problem? part 2 Potential consequences of widespread antepartal use of ampicillin

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.